Sofituzumab (MMUC 1206A) is a humanizedized anti-MUC16 recombinant V-kappa antibody.

Abagovomab (Anti-Human CA-125 Recombinant Antibody) is a murine monoclonal anti-idiotypic antibody, against the tumor-associated antigen, CA-125. Abagovomab is generated by a mouse hybridoma, can imitate the human TAA, CA-125. Abagovomab can elicit humoral and cellular immune responses against ovarian cancer (oc).

Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.

Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC).

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.

Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer.

FP802 is a novel small molecule with significant neuroprotective properties, specifically designed to target and disrupt the TwinF interface within the NMDAR/TRPM4 death signaling complex. This unique mechanism allows FP802 to selectively eliminate extrasynaptic NMDAR (eNMDAR)-mediated toxicity, which is implicated in various neurodegenerative diseases, while preserving the essential physiological functions of synaptic NMDARs. This selectivity makes FP802 a promising therapeutic candidate for conditions involving excitotoxicity and neuronal cell death.

Obtusaquinone (OBT) is a potent antineoplastic agent with significant therapeutic potential, particularly in aggressive cancers such as glioblastoma and breast cancer. Its mechanism of action involves the induction of oxidative stress and endoplasmic reticulum (ER) stress, leading to cancer cell death. OBT has demonstrated promising in vivo activity, including the ability to penetrate the blood-brain barrier (BBB) and target brain tumors, making it a particularly valuable candidate for treating central nervous system (CNS) malignancies.

Dual DDR1 and DDR2 inhibitor 5n is a highly potent and selective small molecule inhibitor targeting both Discoidin Domain Receptor 1 (DDR1) and Discoidin Domain Receptor 2 (DDR2). These receptors are receptor tyrosine kinases (RTKs) that play critical roles in cell proliferation, migration, and extracellular matrix (ECM) remodeling. Dysregulation of DDR1 and DDR2 has been implicated in various diseases, including cancer, fibrosis, and inflammation, making them attractive therapeutic targets.

PLIHZ is a small molecule inhibitor that targets DNAJA1, a member of the heat shock protein 40 (Hsp40) family. Derived from the natural compound plumbagin, PLIHZ specifically binds to the J domain of DNAJA1, which is crucial for its co-chaperone activity with Hsp70. By inhibiting DNAJA1, PLIHZ effectively reduces the levels of DNAJA1 and several conformational mutant p53 (mutp53) proteins, which are often stabilized in cancer cells and contribute to tumorigenesis.

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF).

Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.

Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor.

Amatuximab (MORab-009) is a chimeric, humanized IgG1/k MAb that targets the cell surface mesothelin (MSLN). Mesothelin is a glycosylphosphatidyl inositol (GPI)-anchored membrane glycoprotein, which is present in a restricted set of normal adult tissues such as the mesothelium.